Floatz logo

axl1717

Adenocarcinoma of the Lung

Axelar ABSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

68 Active assets in the Adenocarcinoma of the Lung cohort.

Asset / SponsorPhaseRating
Carboplatin
Guangdong Association of Clinical Trials
Phase 3BBB
Cyclophosphamide
Anusha Kalbasi
Phase 2BBB
CIS-DIAMMINEDICHLOROPLATINUM II
Guangdong Association of Clinical Trials
Phase 3BB
ETOPOSIDE
Guangdong Association of Clinical Trials
Phase 3BB
Nivolumab
Emory University
Phase 3BB

View all 50 →

Same molecule, other indications

axl1717 is also rated in:

squamous cell carcinomaDormant
B
Indicative ·
57 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
anaplastic oligodendrogliomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →